22157.jpg
Global Real World Evidence Solutions Market to Reach US$1.9 Billion by the Year 2027
31 déc. 2020 06h38 HE | Research and Markets
Dublin, Dec. 31, 2020 (GLOBE NEWSWIRE) -- The "Real World Evidence Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the...
22157.jpg
Global Actinic (Solar) Keratosis Clinical Trials Review, H2, 2020 - 10 Companies Involved
23 déc. 2020 03h53 HE | Research and Markets
Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering. "Actinic...
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
21 déc. 2020 07h00 HE | Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...
PRA_StandardLogo_RGB_Pink.png
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
17 déc. 2020 16h02 HE | PRA Health Sciences, Inc.
RALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing...
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
16 déc. 2020 07h00 HE | Ivy Brain Tumor Center
Phoenix, AZ, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute today announced the opening of a Phase 0 clinical trial for patients with newly diagnosed...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
14 déc. 2020 08h30 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Neoleukin.png
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
10 déc. 2020 08h00 HE | Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
22157.jpg
Worldwide Insights on the Bevacizumab Biosimilar Industry to 2025 - Featuring Amgen, AryoGen Pharmed and Biothera Among Others
10 déc. 2020 05h43 HE | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering....
22157.jpg
Outlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others
10 déc. 2020 05h23 HE | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
ehave-logo.png
Ehave Dashboard Enters Final Simulations of Clinical Trials with the Hospital for Sick Children
04 déc. 2020 09h00 HE | Ehave
The Ehave Dashboard has the ability to segment data on-chain, which will allow developers, clinicians, researchers, doctors, hospitals, and universities to provide life-changing solutions to patients....